Buy 4-Aco-DMT is a synthetically produced psychoactive drug and has been suggested to be a potentially useful alternative to psilocybin for pharmacological studies, as they are both believed to be prodrugs of psilocin.
4-Aco-DMT buy 4-Aco-DMT online.
Also psilacetin, 4-acetoxy-DMT, or 4-AcO-DMT,O-Acetylpsilocin). It is a synthetically produced psychoactive drug. It is the acetylated form of the psilocybin mushroom. Alkaloid psilocin and is a lower homolog of 4-AcO-DET, 4-AcO-MiPT and 4-AcO-DiPT.
1 Product name 4-Aco-DMT
2 Full chemical name 3-[2-(Dimethylamino)ethyl]-1H-indol-4-yl acetate
3 Formal Name psilacetin, 4-acetoxy-DMT,O-Acetylpsilocin
4 CAS num 92292-84-7
5 Molecular Formula C14H18N2O2
6 Average mass 246.3049 g·mol−1
7 Purity ≥99.0%
8 Stability 2 years
9 Storage -20°C
10 Formulation A powder solid
11 λmax 221, 315 nm
12 Shipping Wet ice in continental US; may vary elsewhere
It is the acetylated form of the psilocybin mushroom alkaloid psilocin. 4-AcO-DET, 4-AcO-MiPT and 4-AcO-DiPT.
The compound has been suggest by David Nichols to be a potentially useful alternative to psilocybin. For pharmacological studies as they are both believe to be prodrugs of psilocin.
Its structural similarities to psilocin and psilocybin results in an identical subjective effect profile. The three compounds can feel indistinguishable from each other.
This allows 4-AcO-DMT to function as a perfect substitute for psilocybin mushrooms.
4-Acetoxy-N,N-dimethyltryptamine (also known as 4-AcO-DMT, 4-Acetoxy-DMT, O-Acetylpsilocin, and psilacetin) is a novel psychedelic substance of the tryptamine class. 4-AcO-DMT is chemically similar to psilocybin, the active ingredient in psilocybin mushrooms (magic mushrooms). It belongs to a group known as the substituted tryptamines which act by stimulating serotoninreceptors in the brain.
drugs Originally synthesized by chemist Wayne E. Kenney, BAY is a drug which is a cannabinoid receptor agonist developed by Bayer AG. It has analgesic and neuroprotectiveeffects and is used in scientific research, with proposed uses in the treatment of traumatic brain injury.
drugs has analgesic and neuroprotective effects and is used in scientific research, with proposed uses in the treatment of traumatic brain injury. It is a full agonist with around the same potency as CP 55,940 in animal studies, and has fairly high affinity for both CB1 and CB2 receptors, with Ki values of 2.91nM at CB1 and 4.24nM at CB2. It has been licensed to KeyNeurotek Pharmaceuticals for clinical development, and is currently in Phase II trials.But its development appears has stopped.
Originally synthesized by chemist Wayne E. Kenney, is a drug which is a cannabinoid receptor agonist developed by Bayer AG. It has analgesic and neuroprotective effects and is used in scientific research, with proposed uses in the treatment of traumatic brain injury.
Traumatic brain injury (TBI) is the most common cause of mortality and morbidity in adults under 40 years of age in industrialized countries. Worldwide the incidence is increasing, about 9.5 million people are hospitalized per year due to TBI, and the death rate is estimated to be more than one million people per year. Recently has been characterized as a structurally novel, selective and highly potent cannabinoid CB1/CB2 receptor agonist in vitro and in vivo with pronounced neuroprotective efficacy in a rat traumatic brain injury model, showing a therapeutic window of at least 5 h.